Suchergebnisse - "Barrett, Matthew"

PubPharm (300)

1

Phylogenomics and the rise of the angiosperms

enthalten in: Nature | 2024

von Zuntini, A. | Carruthers, T. | Maurin, O. | +98

2

Supine hypertension is longitudinally associated with verbal memory decline in Parkinson disease

enthalten in: Clinical autonomic research : official journal of the Clinical Autonomic Research Society | 2024

von Miller-Patterson, C. | Hsu, J. | Barrett, M. | +3

3

Optimizing Screening for Intrastriatal Interventions in Huntington's Disease Using Predictive Models

enthalten in: Movement disorders : official journal of the Movement Disorder Society | 2024

von Barrett, M. | Negida, A. | Mukhopadhyay, N. | +4

4

Extracorporeal Carbon Dioxide Removal to Avoid Invasive Ventilation During Exacerbations of Chronic Obstructive Pulmonary Disease : VENT-AVOID Trial - A Randomized Clinical Trial

enthalten in: American journal of respiratory and critical care medicine | 2024

von Duggal, A. | Conrad, S. | Barrett, N. | +72

CommentIn: Am J Respir Crit Care Med. 2024 Mar 1;209(5):472-473. - PMID 38285549

5

The gephyrin scaffold modulates cortical layer 2/3 pyramidal neuron responsiveness to single whisker stimulation

enthalten in: Scientific reports | 2024

von Tsai, Y. | Hleihil, M. | Otomo, K. | +11

6

Efficacy of the iron-chelating agent, deferiprone, in patients with Parkinson's disease : A systematic review and meta-analysis

enthalten in: CNS neuroscience & therapeutics | 2024

von Negida, A. | Hassan, N. | Aboeldahab, H. | +7

7

Association of cardiovascular disease management drugs with Lewy body dementia : a case-control study

enthalten in: Brain communications | 2024

von Scholz, S. | Moroz, B. | Saez-Atienzar, S. | +103

8

Efficacy of the iron‐chelating agent, deferiprone, in patients with Parkinson's disease : A systematic review and meta‐analysis

enthalten in: CNS Neuroscience & Therapeutics | 2024

von Negida, A. | Hassan, N. | Aboeldahab, H. | +7

9

Low-Income Older Adults' Vulnerability to Anticholinergic Medication-Associated Frailty

enthalten in: Drugs & aging | 2023

von Sargent, L. | Zimmerman, K. | Mohammed, A. | +12

10

Author Correction : Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial

enthalten in: Nature medicine | 2023

von Dam, T. | Boxer, A. | Golbe, L. | +115

ErratumFor: Nat Med. 2021 Aug;27(8):1451-1457. - PMID 34385707

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[30]